TriangleBiospecimen Collection (NCT05112601)
Biospecimen Collection trial for Endometrial Adenocarcinoma (NCT05112601). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with recurrent endometrial carcinoma and deficient DNA mismatch repair. Serous carcinoma and carcinosarcoma are excluded. Prior immunotherapy is restricted; qualifying PD-1/PD-L1 treatment requires complete response and a treatment-free interval of at least 12 months.
The idea: compare intravenous nivolumab alone with nivolumab plus ipilimumab. They block different immune brakes, aiming to help T cells attack cancer. Researchers compare time before progression and side effects; the combination later continues with nivolumab alone.
This phase 2 study plans 81 patients. NRG Oncology leads; 121 US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.